Managing and preventing sequelae following surgery, radiation therapy (RT), and systemic therapy (e.g., trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, renal failure) requires professionals familiar with head and neck cancers. Limited data are available comparing the efficacy of different chemoradiotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN). Immunotherapy options for recurrent/metastatic nasopharyngeal cancer is a rapidly evolving area of research.

Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.

With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.

Join us for this engaging session led by expert oncology faculty to learn the latest evidence and recommendations with CDK4/6 inhibitors for breast cancer. Insights on how to best mitigate CDK4/6 inhibitor–related adverse events will also be highlighted.